Heat shock protein

Bringing Authentic Sauna Traditions to American Homes: Secret Saunas Launch New Website

Retrieved on: 
Friday, January 12, 2024
Dementia, Health, Hypertension, Life, Temperature, Friends, Jasper, Relaxation, Risk, Perspiration, Longevity, Secrecy, Smoke, Heat shock protein, Tar

Sheridan, Wyoming, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Secret Saunas , an online-only retailer of award-winning sauna heaters, saunas, and hot tubs, is excited to announce the launch of its new website and goal to bring the authentic sauna tradition to American homes.

Key Points: 
  • Sheridan, Wyoming, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Secret Saunas , an online-only retailer of award-winning sauna heaters, saunas, and hot tubs, is excited to announce the launch of its new website and goal to bring the authentic sauna tradition to American homes.
  • This unwavering commitment to authentic materials and construction methods is key to Secret Saunas’ goal of not just sharing the health benefits but continuing to uphold the communal traditions that Finns have perfected over centuries.
  • Some of the saunas at Secret Saunas include:
    Outdoor Saunas: No more shared spaces with strangers; this is a private haven designed to rejuvenate both mind and body.
  • Regardless of a backyard’s dimensions, Secret Saunas have the perfect fit, from compact barrel saunas to expansive cabin retreats.

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant

Retrieved on: 
Monday, December 18, 2023
Cytokine, AACR, Immunotherapy, Research, The central science, Vaccine, Molecular biology, Patent, MD, Doctor of Philosophy, Pharmacology, Biochemistry, University, Society, T cell, OTCQB, Physiology, Heat shock protein, RBS, Chemokine, SITC

The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.

Key Points: 
  • The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.
  • Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee.
  • The research underlying the allowed application was led by Dr. Narendran and his lab team (the Narendran Lab).
  • This work also portends the potential benefit of PV-10 in combination with targeted immunotherapies and antibody-drug conjugates for cancer treatment.

Resolutions passed at the Extraordinary General Meeting

Retrieved on: 
Tuesday, February 15, 2022
New Drug Application, DKK, Food, European Medicines Agency, Heat shock protein, Board of directors, Arimoclomol, Company, SEC, Forward-looking statement, Review, FTD, Extraordinary general meeting, Protein, MAA, Mass meeting, Regulation of tobacco by the U.S. Food and Drug Administration, Endpoint security, Niemann–Pick disease, ADSS, NPC, Hsps, Securities and Exchange Commission (Nigeria), FDA, ODD, Board, Â, Risk, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Association, Nasdaq Copenhagen, BTD, Exercise, Lysosome, Fine chemical, Holding company, Security (finance), EU, Director

Copenhagen,Denmark, February 15, 2022 Orphazyme A/S (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting:

Key Points: 
  • Copenhagen,Denmark, February 15, 2022 Orphazyme A/S (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting:
    Approved the authorizations to the Board of Directors and amendments to the articles of associations, as set out below;
    Elected Andrew Mercieca as new member of the Board of Directors; and
    Approved an authorization to the Chairman of the meeting to file the resolutions passed by the general meeting with the Danish Business Authority.
  • The following authorizations under agenda item 1.2, 1.3 and 1.4, including amendments proposed by the Board of Directors as communicated in company announcement no.
  • ADSs representing Orphazymes shares are listed on Nasdaq U.S. (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA).
  • A marketing authorization application (MAA) for arimoclomol in NPC has been filed with the European Medicines Agency and is under review.

Amendment of proposals put forward at the Extraordinary General Meeting

Retrieved on: 
Monday, February 14, 2022
New Drug Application, DKK, Food, European Medicines Agency, Heat shock protein, Board of directors, Arimoclomol, Company, Article, SEC, Forward-looking statement, Review, FTD, Extraordinary general meeting, Protein, MAA, Endpoint security, Regulation of tobacco by the U.S. Food and Drug Administration, Niemann–Pick disease, ADSS, NPC, Hsps, Securities and Exchange Commission (Nigeria), Director, FDA, ODD, Board, Â, Risk, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Nasdaq Copenhagen, BTD, Exercise, Lysosome, Pharmaceutical industry, Security (finance), EU, Association

The conversion price as determined by the Board of Directors may be above or at the market price at the time of issuance of the convertible bonds.

Key Points: 
  • The conversion price as determined by the Board of Directors may be above or at the market price at the time of issuance of the convertible bonds.
  • The amended authorizations proposed under agenda items 1.2, 1.3 and 1.4 shall be passed by at least two-thirds of the votes cast as well as at least two-thirds of the share capital represented at the Extraordinary General Meeting, cf.
  • ADSs representing Orphazymes shares are listed on Nasdaq U.S. (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA).
  • A marketing authorization application (MAA) for arimoclomol in NPC has been filed with the European Medicines Agency and is under review.

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

Retrieved on: 
Monday, January 31, 2022
CEO, Leadership, Christophe, Patient, Private Securities Litigation Reform Act, Forward-looking statement, NPC, U.S. Securities and Exchange Commission, Food, Endpoint security, Arimoclomol, Sustainability Accounting Standards Board, BTD, SEC, FTD, Lysosome, ODD, CFO, Goal, Hsps, Niemann–Pick disease, Board, MAA, Partnership, New Drug Application, European Medicines Agency, Protein, Company, ADSS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Heat shock protein, FDA, Leo Pharma, Nasdaq Copenhagen, Director, Risk, Review, Management, Pharmaceutical industry, EU

Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.

Key Points: 
  • Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.
  • I would like to thank Christophe for his significant contribution to the Company and wish him all the best in his future endeavors.
  • The Board is very pleased to be able to appoint Anders Vadsholt as the Companys new CEO.
  • CFO, Anders Vadsholt, said: I have enjoyed a strong partnership with Christophe during the past year as we, together with our tenacious and dedicated Orphazyme team, worked towards getting arimoclomol approved in Europe and the US.

Notice to convene Extraordinary General Meeting

Retrieved on: 
Monday, January 24, 2022
U.S. Securities and Exchange Commission, Protein, New Drug Application, Forward-looking statement, SEC, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, BTD, Risk, FTD, Lysosome, ODD, Government, Nasdaq Copenhagen, Extraordinary general meeting, Danish Health Authority, Heat shock protein, Review, Arimoclomol, MAA, Endpoint security, Hsps, Private Securities Litigation Reform Act, Company, Niemann–Pick disease, COVID-19, NPC, Appendix, Food, FDA, ADSS, Degenerative disease, Board, Fine chemical, Security (finance), Pharmaceutical industry, Holding company, EU, Director

We expect the current Covid-19 health risks and government precautions to continue on the date of the Extraordinary General Meeting.

Key Points: 
  • We expect the current Covid-19 health risks and government precautions to continue on the date of the Extraordinary General Meeting.
  • Shareholders wishing to attend the Extraordinary General Meeting in person are encouraged not to bring advisors or other authorized guests to limit the number of physical attendees at the Extraordinary General Meeting.
  • Shareholders may submit written questions to the Companys management before the Extraordinary General Meeting.
  • The notice to convene the Extraordinary General Meeting is attached as well as Appendix 1: Candidate for the Board of Directors.

Major shareholder announcement

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Lipid storage disorders, Rare diseases, Protein folding, Neurological disorders, Neurodegenerative disorders, Heat shock response, Niemann–Pick disease, type C, Heat shock protein, Niemann–Pick disease, Arimoclomol

Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.

Key Points: 
  • Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.
  • The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction.
  • Arimoclomol, the companys lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease.
  • Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.

Major shareholder announcement

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Biology, Lipid storage disorders, Rare diseases, Protein folding, Neurological disorders, Neurodegenerative disorders, Heat shock response, Niemann–Pick disease, type C, Heat shock protein, Niemann–Pick disease, Arimoclomol

Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.

Key Points: 
  • Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.
  • The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction.
  • Arimoclomol, the companys lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease.
  • Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.

Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization

Retrieved on: 
Wednesday, December 2, 2020
Life sciences, Biology, Branches of biology, Brendan Reilly, Chicago, Neurodegeneration, Heat shock protein, Biopharmaceutical

Orphazyme already has recruited more than 30 U.S. employees and recently named three U.S.-based leaders to its global executive team.

Key Points: 
  • Orphazyme already has recruited more than 30 U.S. employees and recently named three U.S.-based leaders to its global executive team.
  • Brendan Reilly, whose Chicago City Council district includes the office, said, "I am proud to welcome Orphazyme's U.S. headquarters to Chicago's 42nd Ward.
  • Orphazyme will bring more than 30 full-time jobs and join a growing community of healthcare companies that call Chicago home.
  • Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.

Tarveda Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Thursday, July 30, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Hsp90, N-(2-Hydroxypropyl) methacrylamide, Heat shock protein, Antineoplastic drugs, Chemistry, Biology

Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.

Key Points: 
  • Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.
  • Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.
  • Tarveda currently has two Pentarin miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.